<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MDM</journal-id>
<journal-id journal-id-type="hwp">spmdm</journal-id>
<journal-id journal-id-type="nlm-ta">Med Decis Making</journal-id>
<journal-title>Medical Decision Making</journal-title>
<issn pub-type="ppub">0272-989X</issn>
<issn pub-type="epub">1552-681X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0272989X11407341</article-id>
<article-id pub-id-type="publisher-id">10.1177_0272989X11407341</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Statistical Methods for Cost-Effectiveness Analyses That Use Data from Cluster Randomized Trials</article-title>
<subtitle>A Systematic Review and Checklist for Critical Appraisal</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Gomes</surname><given-names>Manuel</given-names></name>
<degrees>MSc</degrees>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Grieve</surname><given-names>Richard</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Nixon</surname><given-names>Richard</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Edmunds</surname><given-names>W. J.</given-names></name>
<degrees>PhD</degrees>
</contrib>
</contrib-group>
<aff id="aff1-0272989X11407341">Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK (MG, RG)</aff>
<aff id="aff2-0272989X11407341">Modeling and Simulation Group, Novartis Pharma AG, Basel, Switzerland (RN)</aff>
<aff id="aff3-0272989X11407341">Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK (WJE)</aff>
<author-notes>
<corresp id="corresp1-0272989X11407341">Richard Grieve, PhD, Department of Health Services Research &amp; Policy, London School of Hygiene and Tropical Medicine, 15–17 Tavistock Place, London WC1H 9SH, UK; e-mail: <email>richard.grieve@lshtm.ac.uk</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>32</volume>
<issue>1</issue>
<fpage>209</fpage>
<lpage>220</lpage>
<history>
<date date-type="received">
<day>31</day>
<month>5</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>3</month>
<year>2011</year>
</date>
</history>
<abstract>
<p><bold>Introduction</bold>. The best data for cost-effectiveness analyses (CEAs) of group-level interventions often come from cluster randomized trials (CRTs), where randomization is by cluster (e.g., the hospital attended), not by individual. Methods for these CEAs need to recognize both the correlation between costs and outcomes and that these data may be dependent on the cluster. General checklists and methodological guidance for critically appraising CEA ignore these issues. This article develops a new checklist and applies it in a systematic review of CEAs that use CRTs. <bold>Methods</bold>. The authors developed a checklist for CEAs that use CRTs, informed by a conceptual review of statistical methods. This checklist included criteria such as whether the analysis allowed for both clustering and the correlation between individuals’ costs and outcomes. The authors undertook a systematic literature review of full economic evaluations that used CRTs. The quality of studies was assessed with the new checklist and by the “Drummond checklist.” <bold>Results</bold>. The authors identified 62 papers that met the inclusion criteria. On average, studies satisfied 9 of the 10 criteria for the checklist but only 20% of criteria for the new checklist. More than 40% of studies adopted statistical methods that completely ignored clustering, and 75% disregarded any correlation between costs and outcomes. Only 4 studies employed appropriate statistical methods that allowed for both clustering and correlation. <bold>Conclusions</bold>. Most economic evaluations that use data from CRTs ignored clustering or correlation. Statistical methods that address these issues are available, and their use should be encouraged. The new checklist can supplement generic CEA guidelines and highlight where research practice can be improved.</p>
</abstract>
<kwd-group>
<kwd>statistical methods</kwd>
<kwd>hierarchical models</kwd>
<kwd>cluster analysis</kwd>
<kwd>cost-effectiveness analysis</kwd>
<kwd>systematic reviews</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January–February 2012</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Policy makers worldwide require economic evaluations to help decide which health care technologies to provide.<sup><xref ref-type="bibr" rid="bibr1-0272989X11407341">1</xref>–<xref ref-type="bibr" rid="bibr4-0272989X11407341">4</xref></sup> Economic evaluations are now also used to help identify which public health interventions are priorities<sup><xref ref-type="bibr" rid="bibr5-0272989X11407341">5</xref></sup> and to evaluate different ways of organizing health services.<sup><xref ref-type="bibr" rid="bibr6-0272989X11407341">6</xref>,<xref ref-type="bibr" rid="bibr7-0272989X11407341">7</xref></sup> Methods for the economic evaluation of health care programs are relatively well established and encourage the use of data from randomized controlled trials (RCTs), where patients are individually randomized to alternative interventions.<sup><xref ref-type="bibr" rid="bibr8-0272989X11407341">8</xref>–<xref ref-type="bibr" rid="bibr11-0272989X11407341">11</xref></sup> However, for the evaluation of group-level interventions, a cluster randomized trial (CRT) may be preferred. Here the unit of randomization is the “cluster”—for example, the hospital or primary care physician, not the individual. A cluster design may be chosen because the intervention operates at a group rather than at an individual level (e.g., changing incentives for providers) or if there is a high risk of “contamination” among the individuals within clusters (e.g., evaluating different advertising strategies to encourage smoking cessation).</p>
<p>A fundamental issue in CRTs is that individuals within a cluster are likely to be relatively similar in their characteristics and the care they receive, compared to individuals in different clusters. Individual outcomes or costs within each cluster may therefore be more similar to each other than outcomes or costs from a different cluster. General methodological guidance for CRTs strongly encourages researchers to recognize this clustering in both the design and the analysis of these studies.<sup><xref ref-type="bibr" rid="bibr12-0272989X11407341">12</xref>–<xref ref-type="bibr" rid="bibr17-0272989X11407341">17</xref></sup> Methods that accommodate clustering in the analysis of clinical outcomes are relatively well established in the medical statistics literature.<sup><xref ref-type="bibr" rid="bibr18-0272989X11407341">18</xref>–<xref ref-type="bibr" rid="bibr21-0272989X11407341">21</xref></sup></p>
<p>Cost-effectiveness analyses (CEAs) that use data from CRTs can face particular methodological challenges. These studies require methods that address clustering in both costs and outcomes, recognize the correlation between individual- and cluster-level costs and outcomes,<sup><xref ref-type="bibr" rid="bibr22-0272989X11407341">22</xref>–<xref ref-type="bibr" rid="bibr25-0272989X11407341">25</xref></sup> and make appropriate assumptions about the distribution of these end points.<sup><xref ref-type="bibr" rid="bibr26-0272989X11407341">26</xref>–<xref ref-type="bibr" rid="bibr28-0272989X11407341">28</xref></sup> Statistical methods for CEA that use CRTs have been proposed,<sup><xref ref-type="bibr" rid="bibr29-0272989X11407341">29</xref>–<xref ref-type="bibr" rid="bibr31-0272989X11407341">31</xref></sup> but it is unknown whether suitable methods are used in practice; no previous study has reviewed the methodological quality of these studies. This is a potential concern because as a reanalysis of a CRT-based CEA demonstrated,<sup><xref ref-type="bibr" rid="bibr31-0272989X11407341">31</xref></sup> use of methods that ignore clustering will underestimate statistical uncertainty and can lead to inaccurate point estimates. These methodological concerns face all CEAs that use CRTs, whether they use data from a single CRT or combine that data with other evidence in a decision model.<sup><xref ref-type="bibr" rid="bibr32-0272989X11407341">32</xref></sup></p>
<p>General concerns about methodological standards in CEA have encouraged a plethora of methodological guidelines and critical appraisal criteria that aim to improve methods and reporting transparency.<sup><xref ref-type="bibr" rid="bibr8-0272989X11407341">8</xref>,<xref ref-type="bibr" rid="bibr32-0272989X11407341">32</xref>–<xref ref-type="bibr" rid="bibr37-0272989X11407341">37</xref></sup> However, these generic guidelines do not include sufficiently detailed criteria for CEAs based on CRT, and a more specific tool for appraising the quality of these studies is warranted.</p>
<p>This article aims to develop a new checklist for improving methods in CEAs that use CRTs and applies these criteria in a systematic review of previous studies. This checklist is not intended to replace a generic checklist such as that reported in Drummond and others<sup><xref ref-type="bibr" rid="bibr8-0272989X11407341">8</xref></sup> that covers important, general issues about the overall design and interpretation of a health economic evaluation. Instead, this checklist is proposed for use alongside such general checklists. It covers fundamental statistical issues that arise in CEAs that use data from CRTs. The next section presents the key concepts, the new checklist, and the methods used in the systematic literature review. We then present the results of the review and discuss the findings and the implications for future research.</p>
<sec id="section1-0272989X11407341" sec-type="methods">
<title>Methods</title>
<p>We undertook a conceptual review that had two main purposes: first, to develop criteria for assessing the methodological quality of economic evaluations that use data from CRTs and, second, to identify appropriate methods. The review covered relevant methodological guidance for CRTs<sup><xref ref-type="bibr" rid="bibr12-0272989X11407341">12</xref>–<xref ref-type="bibr" rid="bibr14-0272989X11407341">14</xref>,<xref ref-type="bibr" rid="bibr16-0272989X11407341">16</xref>,<xref ref-type="bibr" rid="bibr18-0272989X11407341">18</xref></sup> and statistical methods for CEA<sup><xref ref-type="bibr" rid="bibr8-0272989X11407341">8</xref>–<xref ref-type="bibr" rid="bibr11-0272989X11407341">11</xref>,<xref ref-type="bibr" rid="bibr38-0272989X11407341">38</xref></sup> and included methodological studies published from 1997 to 2009.</p>
<p>The findings from this conceptual review highlighted that the form of clustering in CRTs is distinct from that in multicenter RCTs where patients are individually randomized, and hence alternative methods are required.<sup><xref ref-type="bibr" rid="bibr39-0272989X11407341">39</xref></sup> In multicenter RCTs, although data may be clustered, individuals within each center are randomized to different treatments; in a CRT, all individuals within a cluster receive the same treatment. This specific form of clustering needs to be anticipated and accounted for in the sample size calculation; otherwise, the study will be underpowered (i.e., it will have less than the nominal power against the study’s alternative hypothesis).<sup><xref ref-type="bibr" rid="bibr40-0272989X11407341">40</xref>,<xref ref-type="bibr" rid="bibr41-0272989X11407341">41</xref></sup> The statistical analysis must also recognize any clustering; otherwise, type I errors will be higher than anticipated, and inference will underestimate the statistical uncertainty.<sup><xref ref-type="bibr" rid="bibr17-0272989X11407341">17</xref>,<xref ref-type="bibr" rid="bibr19-0272989X11407341">19</xref>,<xref ref-type="bibr" rid="bibr42-0272989X11407341">42</xref>,<xref ref-type="bibr" rid="bibr43-0272989X11407341">43</xref></sup> If the CRT has unequal numbers per cluster (imbalance) and a relationship between cluster size and the mean end points in each cluster, methods that ignore clustering can provide biased estimates.<sup><xref ref-type="bibr" rid="bibr44-0272989X11407341">44</xref></sup></p>
<p>Methods developed for analyzing clinical outcomes in CRTs may not be directly applicable to CEAs, which tend to have additional complexities.<sup><xref ref-type="bibr" rid="bibr9-0272989X11407341">9</xref>,<xref ref-type="bibr" rid="bibr11-0272989X11407341">11</xref></sup> First, CEAs would ideally use CRTs with sample sizes calculated according to variances of both costs and effects, with both variances inflated to anticipate clustering.<sup><xref ref-type="bibr" rid="bibr45-0272989X11407341">45</xref>,<xref ref-type="bibr" rid="bibr46-0272989X11407341">46</xref></sup> However, in CRTs (like RCTs), sample sizes are usually only calculated to detect differences between treatment groups in clinical end points rather than costs, where variation relative to the mean tends to be relatively large.<sup><xref ref-type="bibr" rid="bibr45-0272989X11407341">45</xref>–<xref ref-type="bibr" rid="bibr48-0272989X11407341">48</xref></sup> However, a relevant recommendation for CEA is that rather than basing power calculations on a single primary end point, studies should ideally present several sample size calculations and anticipated measures of uncertainty for incremental effectiveness, cost, and measures of cost-effectiveness such as incremental net benefit (INB).<sup><xref ref-type="bibr" rid="bibr49-0272989X11407341">49</xref></sup></p>
<p>Second, cost function theory and previous evidence suggest that resource use, unit costs, and efficiency may vary widely across clusters, leading to potentially higher intracluster correlation coefficients (ICCs)<sup><xref ref-type="fn" rid="fn1-0272989X11407341">*</xref></sup> for costs than for outcomes.<sup><xref ref-type="bibr" rid="bibr50-0272989X11407341">50</xref>–<xref ref-type="bibr" rid="bibr52-0272989X11407341">52</xref></sup> Third, CEA methods need to recognize correlation between costs and outcomes at both the individual and cluster level.<sup><xref ref-type="bibr" rid="bibr23-0272989X11407341">23</xref>–<xref ref-type="bibr" rid="bibr25-0272989X11407341">25</xref>,<xref ref-type="bibr" rid="bibr53-0272989X11407341">53</xref></sup> The size or direction of the correlation may differ according to whether it is at the individual or the cluster level. For example, within clusters, individuals with lower health status may incur higher costs (i.e., at the individual level, there is a strong negative correlation). By contrast, clusters (e.g., hospitals) that have higher mean costs per patient may have on average better outcomes. Fourth, allowing for clustering in separate, univariate estimation of incremental costs and effectiveness is insufficient for correct inferences; methods need to simultaneously recognize correlation and clustering when reporting incremental cost-effectiveness. For example, using a simple nonparametric bootstrap approach that recognizes correlation but ignores clustering would be inadequate.</p>
<p>Finally, statistical methods, including those that acknowledge clustering and correlation, should make plausible assumptions about the distributions of both costs and outcomes.<sup><xref ref-type="bibr" rid="bibr27-0272989X11407341">27</xref>,<xref ref-type="bibr" rid="bibr28-0272989X11407341">28</xref>,<xref ref-type="bibr" rid="bibr54-0272989X11407341">54</xref>–<xref ref-type="bibr" rid="bibr56-0272989X11407341">56</xref></sup> CEAs that use individual patient data (IPD) from a CRT need to carefully consider whether the results are sensitive to alternative assumptions about the distribution of the data. Likewise, for CEAs that use end points from CRTs as parameters in a decision model, any probabilistic sensitivity analysis should carefully justify the distributional assumptions of these input parameters.<sup><xref ref-type="bibr" rid="bibr26-0272989X11407341">26</xref>,<xref ref-type="bibr" rid="bibr54-0272989X11407341">54</xref></sup></p>
<p>To summarize, statistical methods in CEAs that use CRT have to recognize clustering and correlation, as well as make plausible distributional assumptions. Studies can be categorized according to whether the methods can accommodate clustering and correlation. We define a type D study as one that either completely ignores clustering and correlation or only allows for clustering in one of the univariate measures (e.g., incremental outcome). Type C refers to studies that account for correlation between cost and outcomes but ignore clustering, using, for instance, methods such as seemingly unrelated regression<sup><xref ref-type="bibr" rid="bibr25-0272989X11407341">25</xref></sup> without robust standard errors. By contrast, studies may account for clustering in both costs and outcomes but assume they are uncorrelated, for example, by estimating incremental costs and outcomes with separate multilevel models (type B). Ideally, studies should use a statistical method that simultaneously accommodates both clustering and correlation (type A).<sup><xref ref-type="bibr" rid="bibr24-0272989X11407341">24</xref>,<xref ref-type="bibr" rid="bibr57-0272989X11407341">57</xref></sup></p>
<p>The results of CEA based on a CRT can differ according to these methodological choices. A reanalysis<sup><xref ref-type="bibr" rid="bibr31-0272989X11407341">31</xref></sup> of a CRT<sup><xref ref-type="bibr" rid="bibr58-0272989X11407341">58</xref></sup> reported that if the analytical method recognized both clustering and correlation (type A study), the probability that the intervention was cost-effective was 0.52, but when the analysis ignored the clustering and correlation, the corresponding probability was 0.80 (type D study; <xref ref-type="table" rid="table1-0272989X11407341">Table 1</xref>). For analyses that acknowledged clustering but ignored correlation (type B) or accommodated correlation but not clustering (type C), the probabilities of the intervention being cost-effective were 0.51 and 0.79, respectively. This example had low levels of correlation between individual costs and outcomes (ρ = 0.05) but moderate to high levels of clustering (ICCs of 0.05 for outcomes and 0.18 for costs). Here, methods that ignored clustering led to underestimation of uncertainty and also provided different point estimates. More generally, it is unclear a priori whether the choice of method matters, and hence analytical methods that can accommodate both clustering and correlation are required. We describe below several methods that can meet the criteria for type A studies.</p>
<table-wrap id="table1-0272989X11407341" position="float">
<label>Table 1</label>
<caption>
<p>Results from a Cost-Effectiveness Analysis of a Cluster Randomized Trial (PoNDER), Reanalyzed According to Whether the Statistical Methods Accounted for Clustering and Correlation<sup><xref ref-type="bibr" rid="bibr31-0272989X11407341">31</xref></sup></p>
</caption>
<graphic alternate-form-of="table1-0272989X11407341" xlink:href="10.1177_0272989X11407341-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="4">Clustering and Correlation?</th>
</tr>
<tr>
<th/>
<th align="center">Neither (Type D)</th>
<th align="center">Correlation (Type C)</th>
<th align="center">Clustering (Type B)</th>
<th align="center">Both (Type A)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incremental cost, £ (SE)</td>
<td>−72.0 (12.73)</td>
<td>−72.2 (12.64)</td>
<td>−21.4 (28.83)</td>
<td>−22.31 (29.85)</td>
</tr>
<tr>
<td>Incremental QALY (SE)</td>
<td>0.00192 (0.0015)</td>
<td>0.00189 (0.0015)</td>
<td>0.00196 (0.0018)</td>
<td>0.00177 (0.0017)</td>
</tr>
<tr>
<td>Incremental cost per QALY, £</td>
<td>−37,510</td>
<td>−38,175</td>
<td>−10,715</td>
<td>−12,605</td>
</tr>
<tr>
<td>INB (λ = £20,000) (SE)</td>
<td>110.3 (31.93)</td>
<td>110.0 (32.41)</td>
<td>61.46 (44.46)</td>
<td>57.61 (45.83)</td>
</tr>
<tr>
<td><italic>P</italic> (cost-effective)</td>
<td>0.80</td>
<td>0.79</td>
<td>0.51</td>
<td>0.52</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0272989X11407341">
<p>QALY, quality-adjusted life year; INB, incremental net benefit.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section2-0272989X11407341">
<title>Appropriate Statistical Methods for CEA of CRTs</title>
<p>Methods that recognize simultaneously the clustering and correlation between costs and outcomes in estimating incremental cost-effectiveness can either estimate incremental costs and effectiveness on their original scales (bivariate approaches)<sup><xref ref-type="bibr" rid="bibr24-0272989X11407341">24</xref></sup> orcalculate a composite measure of net benefit for each individual (univariate approaches).<sup><xref ref-type="bibr" rid="bibr23-0272989X11407341">23</xref></sup> Although either approach can accommodate clustering, the bivariate approaches are generally more flexible.<sup><xref ref-type="bibr" rid="bibr25-0272989X11407341">25</xref></sup> For example, they can make appropriate distributional assumptions about the distributions of costs as distinct from outcomes. The conceptual review identified 3 main groups of bivariate methods able tohandle clustering and correlation and make appropriate distributional assumptions: multilevel models (MLMs),<sup><xref ref-type="bibr" rid="bibr59-0272989X11407341">59</xref>,<xref ref-type="bibr" rid="bibr60-0272989X11407341">60</xref></sup> generalized estimating equations (GEEs),<sup><xref ref-type="bibr" rid="bibr61-0272989X11407341">61</xref></sup> and the 2-stage nonparametric bootstrap (2SB).<sup><xref ref-type="bibr" rid="bibr62-0272989X11407341">62</xref></sup> Although bivariate GEEs<sup><xref ref-type="bibr" rid="bibr63-0272989X11407341">63</xref></sup> are a recent development, the bootstrap method and bivariate MLMs have been available in the literature for some time.</p>
</sec>
<sec id="section3-0272989X11407341">
<title>Multilevel Models</title>
<p>MLMs can accommodate the hierarchical structure of CEA data from CRTs<sup><xref ref-type="bibr" rid="bibr29-0272989X11407341">29</xref>,<xref ref-type="bibr" rid="bibr31-0272989X11407341">31</xref></sup> (model 1). Suppose that the costs (<italic>c</italic>) and effects (<italic>e</italic>) for the <italic>i</italic>th individual, within the <italic>j</italic>th cluster, in the <italic>k</italic>th trial arm, follow a certain distribution characterized by its mean (µ<italic><sub>ijk</sub></italic>) and standard deviation (σ). The clustering is explicitly recognized by including parameters (<inline-formula id="inline-formula1-0272989X11407341">
<mml:math display="inline" id="math1-0272989X11407341">
<mml:mrow>
<mml:msubsup>
<mml:mi>u</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>c</mml:mi>
</mml:msubsup>
<mml:mo>,</mml:mo>
<mml:msubsup>
<mml:mi>u</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>e</mml:mi>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>) to account for the cluster-specific random effects. The correlation between the individual costs and effects is introduced through the parameter θ. This bivariate model can then report incremental costs (<inline-formula id="inline-formula2-0272989X11407341">
<mml:math display="inline" id="math2-0272989X11407341">
<mml:mrow>
<mml:msubsup>
<mml:mi>β</mml:mi>
<mml:mn>1</mml:mn>
<mml:mi>c</mml:mi>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>) and effects (<inline-formula id="inline-formula3-0272989X11407341">
<mml:math display="inline" id="math3-0272989X11407341">
<mml:mrow>
<mml:msubsup>
<mml:mi>β</mml:mi>
<mml:mn>1</mml:mn>
<mml:mi>e</mml:mi>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>) after allowing for the clustering and correlation.</p>
<p><disp-formula id="disp-formula1-0272989X11407341">
<mml:math display="block" id="math4-0272989X11407341">
<mml:mrow>
<mml:mtable columnalign="left">
<mml:mtr columnalign="left">
<mml:mtd columnalign="left">
<mml:mrow>
<mml:msub>
<mml:mi>c</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>~</mml:mo>
<mml:mi>d</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msubsup>
<mml:mi>μ</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mi>c</mml:mi>
</mml:msubsup>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mi>σ</mml:mi>
<mml:mi>c</mml:mi>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mtext> </mml:mtext>
<mml:msubsup>
<mml:mi>μ</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mi>c</mml:mi>
</mml:msubsup>
<mml:mo>=</mml:mo>
<mml:msubsup>
<mml:mi>β</mml:mi>
<mml:mn>0</mml:mn>
<mml:mi>c</mml:mi>
</mml:msubsup>
<mml:mo>+</mml:mo>
<mml:msubsup>
<mml:mi>β</mml:mi>
<mml:mn>1</mml:mn>
<mml:mi>c</mml:mi>
</mml:msubsup>
<mml:msub>
<mml:mi>t</mml:mi>
<mml:mi>k</mml:mi>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msubsup>
<mml:mi>u</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>c</mml:mi>
</mml:msubsup>
</mml:mrow>
</mml:mtd>
</mml:mtr>
<mml:mtr columnalign="left">
<mml:mtd columnalign="left">
<mml:mrow>
<mml:msub>
<mml:mi>e</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>~</mml:mo>
<mml:mi>d</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msubsup>
<mml:mi>μ</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mi>e</mml:mi>
</mml:msubsup>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mi>σ</mml:mi>
<mml:mi>e</mml:mi>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mtext> </mml:mtext>
<mml:msubsup>
<mml:mi>μ</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mi>e</mml:mi>
</mml:msubsup>
<mml:mo>=</mml:mo>
<mml:msubsup>
<mml:mi>β</mml:mi>
<mml:mn>0</mml:mn>
<mml:mi>e</mml:mi>
</mml:msubsup>
<mml:mo>+</mml:mo>
<mml:msubsup>
<mml:mi>β</mml:mi>
<mml:mn>1</mml:mn>
<mml:mi>e</mml:mi>
</mml:msubsup>
<mml:msub>
<mml:mi>t</mml:mi>
<mml:mi>k</mml:mi>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msubsup>
<mml:mi>u</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>e</mml:mi>
</mml:msubsup>
<mml:mo>+</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>c</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msubsup>
<mml:mi>μ</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mi>c</mml:mi>
</mml:msubsup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-0272989X11407341" xlink:href="10.1177_0272989X11407341-eq1.tif"/>
</disp-formula></p>
<p>Model (1) can be estimated and interpreted with a frequentist approach, generally implemented by maximum likelihood,<sup><xref ref-type="bibr" rid="bibr57-0272989X11407341">57</xref></sup> or from a Bayesian perspective, typically implemented with Markov chain Monte Carlo (MCMC) methods.<sup><xref ref-type="bibr" rid="bibr24-0272989X11407341">24</xref></sup> Fitting MLMs by MCMC in WinBUGS offers a particularly flexible alternative because the wide range of parametric distributions available can help the study make more plausible distributional assumptions than estimating MLMs by maximum likelihood.<sup><xref ref-type="bibr" rid="bibr31-0272989X11407341">31</xref></sup></p>
</sec>
<sec id="section4-0272989X11407341">
<title>Generalized Estimating Equations</title>
<p>GEEs are a flexible extension of likelihood-based generalized linear models (GLMs) that can accommodate clustered data<sup><xref ref-type="bibr" rid="bibr61-0272989X11407341">61</xref>,<xref ref-type="bibr" rid="bibr64-0272989X11407341">64</xref></sup> and are often used to analyze clinical outcomes in CRTs.<sup><xref ref-type="bibr" rid="bibr18-0272989X11407341">18</xref>,<xref ref-type="bibr" rid="bibr43-0272989X11407341">43</xref>,<xref ref-type="bibr" rid="bibr65-0272989X11407341">65</xref>,<xref ref-type="bibr" rid="bibr66-0272989X11407341">66</xref></sup> GEEs take a marginal rather than a conditional approach (i.e., they estimate marginal effects averaged over the population of individuals). Then, the estimated coefficients (e.g., treatment effect) report how the population-averaged outcome, rather than one individual’s outcome, responds to the covariate (e.g., treatment indicator).<sup><xref ref-type="fn" rid="fn2-0272989X11407341">†</xref></sup> Bivariate GEEs can recognize correlations between dependent end points and area potential alternative for CEAs that use CRT data.<sup><xref ref-type="bibr" rid="bibr63-0272989X11407341">63</xref></sup> These GEEs rely on the general property of population-averaged GEE models in that they provide asymptotically consistent parameter estimates even if the working correlation matrix is misspecified as long as the model, the relationship between the marginal mean and the linear predictor, is correct.</p>
<p>When the parametric assumptions underlying MLMs are not satisfied, GEEs can be relatively statistically efficient (i.e., they may report smaller variances). By contrast, a GEE may be less efficient than an MLM that makes plausible parametric assumptions. A further concern with GEEs is that the asymptotic assumptions rely on the study having sufficient clusters. Methodological guidelines generally recommend that for the GEE to provide reliable estimates, the CRT should have at least 20 clusters.<sup><xref ref-type="bibr" rid="bibr19-0272989X11407341">19</xref>,<xref ref-type="bibr" rid="bibr42-0272989X11407341">42</xref>,<xref ref-type="bibr" rid="bibr43-0272989X11407341">43</xref>,<xref ref-type="bibr" rid="bibr65-0272989X11407341">65</xref></sup></p>
</sec>
<sec id="section5-0272989X11407341">
<title>The 2-Stage Nonparametric Bootstrap</title>
<p>The 2SB, proposed by Davison and Hinkley,<sup><xref ref-type="bibr" rid="bibr62-0272989X11407341">62</xref></sup> involves resampling clusters and then individuals (both with replacement). This 2-stage process accounts for clustering by recognizing that the sample variance is partitioned within and between clusters. Mean end points are then calculated arithmetically across the bootstrap resamples. The 2SB can account for the correlation between costs and effects by resampling them in pairs.<sup><xref ref-type="bibr" rid="bibr68-0272989X11407341">68</xref></sup> This algorithm was proposed for balanced clusters (equal numbers per cluster), and it is unknown from the methodological literature whether the 2SB performs well when the clusters are highly imbalanced. Similarly, it is unclear how the 2SB performs when the number of clusters is small, particularly when costs are highly skewed.<sup><xref ref-type="bibr" rid="bibr30-0272989X11407341">30</xref>,<xref ref-type="bibr" rid="bibr69-0272989X11407341">69</xref>,<xref ref-type="bibr" rid="bibr70-0272989X11407341">70</xref></sup></p>
<p>Rather than keeping costs and outcomes on their original scales, net benefits (NB) can be calculated for each individual as either net monetary benefits (NMB) or net health benefits (NHB).<sup><xref ref-type="bibr" rid="bibr23-0272989X11407341">23</xref></sup> Clustering can then be recognized in univariate versions of any of the bivariate methods listed above. For example, the MLM in equation (1) could be rewritten as</p>
<p><disp-formula id="disp-formula2-0272989X11407341">
<mml:math display="block" id="math5-0272989X11407341">
<mml:mrow>
<mml:mi>N</mml:mi>
<mml:msub>
<mml:mi>B</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>~</mml:mo>
<mml:mi>d</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msubsup>
<mml:mi>μ</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>N</mml:mi>
<mml:mi>B</mml:mi>
</mml:mrow>
</mml:msubsup>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mi>σ</mml:mi>
<mml:mrow>
<mml:mi>N</mml:mi>
<mml:mi>B</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mtext> </mml:mtext>
<mml:msubsup>
<mml:mi>μ</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
<mml:mi>k</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>N</mml:mi>
<mml:mi>B</mml:mi>
</mml:mrow>
</mml:msubsup>
<mml:mo>=</mml:mo>
<mml:msubsup>
<mml:mi>β</mml:mi>
<mml:mn>0</mml:mn>
<mml:mrow>
<mml:mi>N</mml:mi>
<mml:mi>B</mml:mi>
</mml:mrow>
</mml:msubsup>
<mml:mo>+</mml:mo>
<mml:msubsup>
<mml:mi>β</mml:mi>
<mml:mn>1</mml:mn>
<mml:mrow>
<mml:mi>N</mml:mi>
<mml:mi>B</mml:mi>
</mml:mrow>
</mml:msubsup>
<mml:msub>
<mml:mi>t</mml:mi>
<mml:mi>k</mml:mi>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msubsup>
<mml:mi>u</mml:mi>
<mml:mi>j</mml:mi>
<mml:mrow>
<mml:mi>N</mml:mi>
<mml:mi>B</mml:mi>
</mml:mrow>
</mml:msubsup>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-0272989X11407341" xlink:href="10.1177_0272989X11407341-eq2.tif"/>
</disp-formula></p>
<p>The 2SB algorithm described could also be implemented by resampling individual net benefits rather than pairs of costs and outcomes. A univariate GEE with net benefits as the dependent variable could be applied to estimate INBs. However, although these univariate models can allow for correlation and clustering, they are more restrictive<sup><xref ref-type="bibr" rid="bibr25-0272989X11407341">25</xref>,<xref ref-type="bibr" rid="bibr38-0272989X11407341">38</xref></sup>; for example, these methods do not allow for different covariates to be included in the estimation of incremental costs v. effectiveness.<sup><xref ref-type="bibr" rid="bibr24-0272989X11407341">24</xref>,<xref ref-type="bibr" rid="bibr25-0272989X11407341">25</xref></sup></p>
</sec>
<sec id="section6-0272989X11407341">
<title>Cluster-Level Summaries and Statistical Tests</title>
<p>Individual-level analyses using parametric or nonparametric statistical tests adjusted for clustering (e.g., adjusted 2-sample <italic>t</italic> test or adjusted χ<sup><xref ref-type="bibr" rid="bibr2-0272989X11407341">2</xref></sup> test) or cluster-level summary statistics (e.g., 2-sample <italic>t</italic> test, Wilcoxon rank sum test) are simple to implement and can be appropriate for the analysis of clinical outcomes in CRTs.<sup><xref ref-type="bibr" rid="bibr12-0272989X11407341">12</xref>,<xref ref-type="bibr" rid="bibr14-0272989X11407341">14</xref></sup> However, for CEA, these methods lack the flexibility required to address key statistical issues such as the correlation between individual costs and outcomes.</p>
</sec>
<sec id="section7-0272989X11407341">
<title>New Checklist for Economic Evaluations That Use Data from CRTs</title>
<p>On the basis of the conceptual review, we developed specific criteria for assessing how well CEAs that use CRT address key methodological issues not covered in generic checklists. Provisional versions of the checklist were reviewed by a panel with relevant expertise (medical statisticians, health economists, and epidemiologists). In addition, 3 researchers not involved in developing the checklist piloted the tool on 15 studies. The final version of the checklist is reported in <xref ref-type="table" rid="table2-0272989X11407341">Table 2</xref>. The checklist gives “credit” to those CEAs that met recommended practice and both used appropriate statistical methods and reported them transparently in the study.<sup><xref ref-type="bibr" rid="bibr1-0272989X11407341">1</xref>,<xref ref-type="bibr" rid="bibr8-0272989X11407341">8</xref>,<xref ref-type="bibr" rid="bibr32-0272989X11407341">32</xref>,<xref ref-type="bibr" rid="bibr37-0272989X11407341">37</xref></sup> To ascertain whether a study uses appropriate methods but fails to report them in the main CEA paper, the checklist can also be applied using information from additional published sources such as the main CRT paper, previous CEA, or reports such as those published by the National Institute of Health Research Health Technology Assessment Programme.</p>
<table-wrap id="table2-0272989X11407341" position="float">
<label>Table 2</label>
<caption>
<p>Proposed Checklist for Cost-Effectiveness Analyses That Use Data from Cluster Randomized Trials</p>
</caption>
<graphic alternate-form-of="table2-0272989X11407341" xlink:href="10.1177_0272989X11407341-table2.tif"/>
</table-wrap>
<p>Question 1 in the checklist assesses whether sample size calculations have incorporated any clustering anticipated in outcomes and costs.<sup><xref ref-type="bibr" rid="bibr40-0272989X11407341">40</xref>,<xref ref-type="bibr" rid="bibr41-0272989X11407341">41</xref>,<xref ref-type="bibr" rid="bibr45-0272989X11407341">45</xref>,<xref ref-type="bibr" rid="bibr46-0272989X11407341">46</xref></sup> Question 2 appraises whether clustering has been recognized in the univariate analysis of incremental costs and outcomes.<sup><xref ref-type="bibr" rid="bibr12-0272989X11407341">12</xref>,<xref ref-type="bibr" rid="bibr14-0272989X11407341">14</xref>,<xref ref-type="bibr" rid="bibr18-0272989X11407341">18</xref>–<xref ref-type="bibr" rid="bibr20-0272989X11407341">20</xref>,<xref ref-type="bibr" rid="bibr71-0272989X11407341">71</xref></sup> Question 3 assesses whether the statistical methods accounted for the correlation between individual costs and effects.<sup><xref ref-type="bibr" rid="bibr23-0272989X11407341">23</xref>–<xref ref-type="bibr" rid="bibr25-0272989X11407341">25</xref>,<xref ref-type="bibr" rid="bibr68-0272989X11407341">68</xref></sup> Even if a study has allowed for clustering in the univariate end points (question 2) or correlation between costs and effects (question 3), it may fail to recognize both clustering and correlation in the joint estimation of costs and effects or in the estimation of INBs. Question 4 considers whether methods allowed simultaneously for clustering and correlation when estimating incremental cost-effectiveness.<sup><xref ref-type="bibr" rid="bibr29-0272989X11407341">29</xref>–<xref ref-type="bibr" rid="bibr31-0272989X11407341">31</xref></sup> A study that uses methods that meet the criterion for question 4 would also be assumed to satisfy the criteria for questions 2 and 3. Question 5 considers whether the study has used statistical methods that made explicit, appropriate assumptions about the distribution of costs and outcomes.<sup><xref ref-type="bibr" rid="bibr26-0272989X11407341">26</xref>–<xref ref-type="bibr" rid="bibr28-0272989X11407341">28</xref>,<xref ref-type="bibr" rid="bibr54-0272989X11407341">54</xref>,<xref ref-type="bibr" rid="bibr55-0272989X11407341">55</xref></sup></p>
<p>The checklist can be scored to give a total score for each paper. Each paper can be credited with 1 point for each criterion met (0.5 points for each subquestion) or otherwise zero, with the scores then summed across the criteria to give a total score out of 5. Web Appendix 1 offers guidance on how to judge whether each criterion is met.</p>
</sec>
<sec id="section8-0272989X11407341">
<title>Systematic Review of CEAs That Use CRT</title>
<p>We conducted a systematic literature review of economic evaluations that used data from CRTs. The review included full economic evaluations<sup><xref ref-type="bibr" rid="bibr8-0272989X11407341">8</xref></sup> as they provide information on the relative tradeoffs between the effect of the intervention on costs and outcomes and hence the most relevant information for health care decision making.<sup><xref ref-type="bibr" rid="bibr22-0272989X11407341">22</xref></sup> The review satisfied the requirements of a systematic literature review, according to the updated PRISMA statement.<sup><xref ref-type="bibr" rid="bibr72-0272989X11407341">72</xref></sup></p>
</sec>
<sec id="section9-0272989X11407341">
<title>Search Strategy</title>
<p>A consistent and transparent literature search was undertaken over a wide range of databases in health economics, public health, and medicine used in previous systematic reviews in economic evaluation.<sup><xref ref-type="bibr" rid="bibr73-0272989X11407341">73</xref>–<xref ref-type="bibr" rid="bibr75-0272989X11407341">75</xref></sup> The databases included the Health Economic Evaluations Database (HEED), NHS Economic Evaluations Database (NEED), EconLit, EMBASE, PubMed, MedLine, Scopus, and Web of Science. In addition, nonpublished literature was also searched in working papers databases (e.g., Ideas, NetEc, EconWPA) and Conference Papers Index (CPI). The search strategy combined 2 sets of free-text terms related to 1) economic evaluations, where terminology used in previous search strategies<sup><xref ref-type="bibr" rid="bibr75-0272989X11407341">75</xref>,<xref ref-type="bibr" rid="bibr76-0272989X11407341">76</xref></sup> was extended; 2) cluster randomized trials, where the terms <italic>cluster, group, community, clinic, center</italic>, or <italic>area</italic> were used to identify CRTs that included any of these terms in the title or abstract. Web Appendix 2 describes the search strategy for MedLine, which was slightly modified for the other databases.</p>
</sec>
<sec id="section10-0272989X11407341">
<title>Inclusion Criteria</title>
<p>To minimize the risk of missing potentially relevant economic evaluations, the inclusion criteria were broad, and the search was conducted on all the available evidence up to the end of 2009. Titles and abstracts were screened to check whether the study met the following inclusion criteria:</p>
<list id="list1-0272989X11407341" list-type="order">
<list-item>
<p>Study must be undertaken alongside a CRT.</p>
</list-item>
<list-item>
<p>Paper must compare both cost and outcomes of alternative interventions.</p>
</list-item>
<list-item>
<p>Results must be reported on an incremental basis.</p>
</list-item>
<list-item>
<p>The paper must be a cost-effectiveness, cost-utility, or cost-benefit analysis but not a cost minimization or cost-consequence analysis.</p>
</list-item>
<list-item>
<p>Paper can be published in any language but with an abstract in English.</p>
</list-item>
<list-item>
<p>Several papers that use data from the same CRT can be included, provided each of them reports results not published elsewhere.</p>
</list-item>
</list>
<p>The title and abstract screening were conducted by one reviewer. To check the reliability of the way the inclusion criteria were applied at the abstract screening stage, the abstracts for those articles excluded by the first reviewer were rescreened by a second reviewer. At the abstract and title screening stage, both reviewers were blinded to the authorship. There were no disagreements in the articles excluded. Full-text review and data extraction were conducted by the first reviewer, who at this stage was not blinded to the authorship. The selected articles were critically appraised with the Drummond checklist,<sup><xref ref-type="bibr" rid="bibr8-0272989X11407341">8</xref></sup> chosen because it has been commonly used to critically appraise CEA. The economic evaluation papers were critically appraised by both reviewers independently, using the cluster-specific checklist. The reliability of the checklist was good; the reviewers only disagreed on whether a certain criterion was met in 10 studies (κ &gt; 0.9). These disagreements were resolved in consultation with a third reviewer. Finally, to consider the possibility that studies may have used appropriate methods but failed to report them in the main CEA paper, we reapplied the cluster-specific checklist using additional information from further sources, such as the accompanying clinical paper or previous economic evaluations of the same study.</p>
<p>The review reported the overall results of critically appraising the papers with both checklists. In addition, several prior hypotheses were considered concerning the context of the studies. To assess whether studies had improved since the publication of several key papers on relevant statistical methods, results were compared over time (post 2005 v. 2005 or earlier). Other prespecified hypotheses were whether the results differed according to the type of journal in which the CEA was published (medical v. other) and according to the overall study design (CEA that used IPD v. alternatives such as decision models that used summary inputs from CRTs).</p>
</sec>
</sec>
<sec id="section11-0272989X11407341" sec-type="results">
<title>Results</title>
<p>The database search strategy yielded 682 unique articles, 573 of which were excluded after screening the title and abstract and a further 47 after full-text review. The most common reason for exclusion was that studies were either not based on CRTs or were not full economic evaluations (<xref ref-type="fig" rid="fig1-0272989X11407341">Figure 1</xref>). A total of 62 papers (54 CRTs) satisfied the inclusion criteria and were included in the review (see Web Appendix 3 for a full list). For 45 of the 62 papers, we identified a relevant accompanying article for review such as the main clinical paper on the CRT.</p>
<fig id="fig1-0272989X11407341" position="float">
<label>Figure 1</label>
<caption>
<p>Study selection flow diagram. CRT, cluster randomized trial.</p>
</caption>
<graphic xlink:href="10.1177_0272989X11407341-fig1.tif"/>
</fig>
<p>The selected papers were published from 1997 to 2009 (inclusive), mainly in medical and public health journals (<xref ref-type="table" rid="table3-0272989X11407341">Table 3</xref>). The economic evaluations covered a wide range of group-level interventions: alternative ways of organizing health care services (e.g., cost-sharing incentives programs), different disease management programs, screening, health care promotion strategies, and evaluations of clinical guidelines. More than two-thirds of papers were based on IPD from the CRT; the remaining studies used summary data in decision-analytic models or simply reported aggregated, deterministic measures.</p>
<table-wrap id="table3-0272989X11407341" position="float">
<label>Table 3</label>
<caption>
<p>Characteristics of the Studies Included in the Review (<italic>n</italic> = 62)</p>
</caption>
<graphic alternate-form-of="table3-0272989X11407341" xlink:href="10.1177_0272989X11407341-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<tbody>
<tr>
<th align="left">Characteristic</th>
<th align="center">No. (%)</th>
</tr>
<tr>
<td colspan="2">Year</td>
</tr>
<tr>
<td> 2009</td>
<td>12 (19.4)</td>
</tr>
<tr>
<td> 2008</td>
<td>5 (8.1)</td>
</tr>
<tr>
<td> 2007</td>
<td>9 (14.5)</td>
</tr>
<tr>
<td> 2006</td>
<td>10 (16.1)</td>
</tr>
<tr>
<td> 2005</td>
<td>7 (11.3)</td>
</tr>
<tr>
<td> Before 2004</td>
<td>9 (14.5)</td>
</tr>
<tr>
<td colspan="2">Journal</td>
</tr>
<tr>
<td> Medical</td>
<td>36 (58.1)</td>
</tr>
<tr>
<td> Health economics</td>
<td>11 (17.7)</td>
</tr>
<tr>
<td> Public health</td>
<td>14 (22.6)</td>
</tr>
<tr>
<td> Statistics</td>
<td>1 (1.6)</td>
</tr>
<tr>
<td colspan="2">Intervention type</td>
</tr>
<tr>
<td> Health services</td>
<td>21 (33.9)</td>
</tr>
<tr>
<td> Disease management</td>
<td>16 (25.8)</td>
</tr>
<tr>
<td> Screening</td>
<td>9 (17.7)</td>
</tr>
<tr>
<td> Prevention</td>
<td>11 (14.5)</td>
</tr>
<tr>
<td> Guidelines</td>
<td>6 (8.1)</td>
</tr>
<tr>
<td colspan="2">Study design</td>
</tr>
<tr>
<td> IPD (individual patient data)</td>
<td>42 (67.7)</td>
</tr>
<tr>
<td> Decision model</td>
<td>8 (12.9)</td>
</tr>
<tr>
<td> Aggregate analysis</td>
<td>12 (19.4)</td>
</tr>
</tbody>
</table>
</table-wrap>
<sec id="section12-0272989X11407341">
<title>Results from Applying the Checklists</title>
<p>On average, the papers met 90% of the Drummond checklist criteria. When the studies were assessed using the cluster-specific checklist, 20% of the criteria were met; the median total quality score was 1 out of 5. <xref ref-type="fig" rid="fig2-0272989X11407341">Figure 2</xref> describes the distributions of the criteria met for each checklist. The distribution of the criteria met is heavily left skewed for the Drummond checklist and right skewed for the cluster-specific checklist.</p>
<fig id="fig2-0272989X11407341" position="float">
<label>Figure 2</label>
<caption>
<p>Methodological quality of the selected papers using the Drummond checklist and our proposed checklist.</p>
</caption>
<graphic xlink:href="10.1177_0272989X11407341-fig2.tif"/>
</fig>
<p>According to the Drummond checklist, studies improved after 2005 (a median of 10 v. 9 criteria met; Mann-Whitney test, <italic>P</italic> = 0.02). However, with the new checklist, the scores for studies conducted after2005 were no higher than for earlier years (median = 1, interquartile range [IQR] = 2 v. median = 1, IQR = 1.5; <italic>P</italic> = 0.45). For articles published in health economics or public health journals, the median quality score from the new checklist was not statistically different from those published in specialist medical journals (median = 1, IQR = 1.5 v. median = 1, IQR = 1.5; <italic>P</italic> = 0.31). However, studies that used IPD had a higher median quality score than those using summary estimates from the CRT in decision-analytic models or other forms of aggregated analyses (median = 1, IQR = 1.5 v. median = 0.5, IQR = 1; <italic>P</italic> = 0.002).</p>
<p><xref ref-type="table" rid="table4-0272989X11407341">Table 4</xref> presents disaggregated results according to whether the study met each criterion in the checklist, first according to the information reported in the main CEA paper and, second, according to additional information available from other sources. The results, in general, were similar across these 2 sets of sources apart from for the criterion on the sample size for outcomes; more than 80% of the economic evaluations did not report that clustering was recognized in sample size calculations, whereas once supplementary papers such as the corresponding clinical paper were considered, less than 40% of studies failed this criterion.</p>
<table-wrap id="table4-0272989X11407341" position="float">
<label>Table 4</label>
<caption>
<p>Results from Applying the Cluster Randomized Trial Checklist to the Economic Evaluation Paper and the Economic Evaluation and Supplementary Sources</p>
</caption>
<graphic alternate-form-of="table4-0272989X11407341" xlink:href="10.1177_0272989X11407341-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Question</th>
<th align="center">Economic Evaluation</th>
<th align="center">Economic Evaluation and Supplementary Papers</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3">1. Clustering recognized in the sample size calculation for:</td>
</tr>
<tr>
<td> a) outcomes</td>
<td>12 (19.4)</td>
<td>38 (61.3)</td>
</tr>
<tr>
<td> b) costs</td>
<td>0</td>
<td>7 (11.3)</td>
</tr>
<tr>
<td colspan="3">2. Clustering accounted for in univariate analysis of:</td>
</tr>
<tr>
<td> a) outcomes</td>
<td>32 (51.6)</td>
<td>36 (58.1)</td>
</tr>
<tr>
<td> b) costs</td>
<td>20 (32.3)</td>
<td>20 (32.3)</td>
</tr>
<tr>
<td>3. Accounted for correlation between costs and outcomes</td>
<td>16 (25.8)</td>
<td>16 (25.8)</td>
</tr>
<tr>
<td>4. Accounted for clustering and correlation for cost-effectiveness</td>
<td>4 (6.5)</td>
<td>4 (6.5)</td>
</tr>
<tr>
<td colspan="3">5. Appropriate assumptions about the distribution of:</td>
</tr>
<tr>
<td> a) outcomes</td>
<td>10 (16.1)</td>
<td>14 (22.6)</td>
</tr>
<tr>
<td> b) costs</td>
<td>17 (27.4)</td>
<td>20 (32.3)</td>
</tr>
<tr>
<td>Median (interquartile range) total score</td>
<td>1 (1.5)</td>
<td>1.25 (1.5)</td>
</tr>
<tr>
<td>Mean (SD) total score</td>
<td>1.1 (1.0)</td>
<td>1.41 (1.2)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0272989X11407341">
<p>Data presented as number (%) of studies that met each criterion and total score (<italic>n</italic> = 62), except where indicated otherwise.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>More than 40% of papers completely ignored clustering in the analyses (37% when supplementary information was also considered). Almost 70% ignored clustering in the univariate analysis of costs and 50% in the univariate analysis of outcomes. Those studies that allowed for clustering tended to use multilevel models or GEEs. A total of 37 papers reported ICCs for outcomes; 5% suggested that levels of clustering were “high” (ICC &gt; 0.1), 65% that they were “moderate” (0.01 &lt; ICC ≤ 0.1), and 30% that they were “low” (ICC ≤ 0.01).</p>
<p>More than 70% of papers neglected the correlation between costs and outcomes (<xref ref-type="table" rid="table4-0272989X11407341">Table 4</xref>). We found only 4 studies (6.5%) that used statistical methods (bivariate MLMs and 2SB) that allowed for both clustering and correlation in the estimation of incremental costs and outcomes, of which 3 did notmake appropriate distributional assumptions. Overall, more than 60% of studies failed to make appropriate assumptions about the distribution of the costs or outcomes.</p>
<p><xref ref-type="fig" rid="fig3-0272989X11407341">Figure 3</xref> summarizes the main findings. The majority of papers (58%) were defined as type D studies as they either ignored both clustering and correlation or neglected correlation and only accounted for clustering in one of the outcomes (costs or effects). One-fifth of papers reported accounting for clustering in the univariate analyses of both costs and effects but did not allow for correlation (type B), and 15% recognized correlation but failed to correctly acknowledge the clustering (type C). Only 4 studies appropriately accounted for both clustering and correlation in the estimation of cost and effects (type A).</p>
<fig id="fig3-0272989X11407341" position="float">
<label>Figure 3</label>
<caption>
<p>The proportions of papers that allow for clustering and correlation (n = 62).</p>
</caption>
<graphic xlink:href="10.1177_0272989X11407341-fig3.tif"/>
</fig>
</sec>
</sec>
<sec id="section13-0272989X11407341" sec-type="discussion">
<title>Discussion</title>
<p>This study makes 2 important contributions to the methodological literature on CEA. First, this article presents a tool to assess and help improve the quality of economic evaluations that use data from CRTs. Second, our systematic review finds that although the methodological quality of papers was generally good when judged against the Drummond checklist, it was poor when assessed against the cluster-specific checklist. The main purpose of the cluster-specific checklist is to summarize how well studies address the key statistical issues at a particular point in time. This purpose is reflected in the way summary scores can be calculated with each item given equal weight.<sup><xref ref-type="bibr" rid="bibr36-0272989X11407341">36</xref></sup> The checklist could be used to assess whether studies improve over time, by comparing the overall score but also specific components, such as the proportion of studies that allow for both clustering and correlation (type A studies).</p>
<p>This review followed previous recommendations for critical appraisal and judged study quality not just according to whether studies used appropriate methods but also whether they reported them transparently. It is conceivable that the studies <italic>used</italic> sound methods but did not <italic>report</italic> them in the main economic evaluation paper. We therefore considered additional papers in the critical appraisal, particularly the main clinical paper reporting the CRT results. However, we did not find any significant improvement in the quality of the methods, which raises the following question: Were appropriate methods available?</p>
<p>The conceptual review identified 3 groups of potential methods (MLMs, GEEs, and the 2SB) that can handle the specific form of clustering present in CRTs, correlation between costs and effects and skewed data. Methodological guidance on the use of these methods to analyze data from CRTs has been established for some time in the literature.<sup><xref ref-type="bibr" rid="bibr12-0272989X11407341">12</xref>,<xref ref-type="bibr" rid="bibr14-0272989X11407341">14</xref>,<xref ref-type="bibr" rid="bibr18-0272989X11407341">18</xref>,<xref ref-type="bibr" rid="bibr62-0272989X11407341">62</xref>,<xref ref-type="bibr" rid="bibr77-0272989X11407341">77</xref></sup> However, these methods have yet to permeate applied health economic evaluations that use data from CRTs. Indeed, we found no evidence that theuse of these potentially appropriate methods improved over time. The most flexible way to implement these methods is in bivariate approaches that jointly estimate costs and effects. Alternatively, net benefits can be calculated for each individual, and then any of the above methods can be applied to allow for clustering in the net benefit estimates. Although the latter approach lacks flexibility, allowing for clustering using <italic>any</italic> of the approaches outlined would improve on the status quo.</p>
<p>The finding that, in practice, most CEAs fail to use or report appropriate statistical methods is consistent with previous reviews on design and analysis of CRTs and statistical methods in CEA based on RCTs.<sup><xref ref-type="bibr" rid="bibr17-0272989X11407341">17</xref>,<xref ref-type="bibr" rid="bibr33-0272989X11407341">33</xref>,<xref ref-type="bibr" rid="bibr78-0272989X11407341">78</xref>,<xref ref-type="bibr" rid="bibr79-0272989X11407341">79</xref></sup> The poor quality of CEA based on CRTs may reflect the relative lack of attention given to statistical methods for CEAs of CRTs. Only 1 study<sup><xref ref-type="bibr" rid="bibr29-0272989X11407341">29</xref></sup> has attempted to compare alternative statistical methods for CEAs from CRTs, but the study used a CRT with relatively “ideal” characteristics, not representative of the majority of studies we reviewed. That CRT had many balanced clusters (<italic>n</italic> = 50), and so the methodological comparison offered limited generalizability. For example, more than 70% of studies in our review had imbalanced clusters. Likewise, Flynn and Peters<sup><xref ref-type="bibr" rid="bibr30-0272989X11407341">30</xref></sup> only considered the 2SB for circumstances when CRTs have balanced clusters. A recent study proposed MLMs for economic evaluations of CRTs and suggested that this approach led to different cost-effectiveness results compared to methods that ignored clustering.<sup><xref ref-type="bibr" rid="bibr31-0272989X11407341">31</xref></sup> However, this study did not consider alternative approaches (e.g., GEEs or 2SB). Research is currently under way to investigate the relative merits of alternative statistical methods for CEA from CRTs across the range of circumstances representative of the studies reviewed.</p>
<p>Although this article has developed criteria for improving methods for economic evaluations that use CRTs and carefully applied them in a systematic literature review, it does have some limitations. First, the checklist does not attempt to cover all the statistical issues that can arise when designing or analyzing an economic evaluation alongside CRTs. For example, it does not include questions on whether the study accounted for missing or censored data.<sup><xref ref-type="bibr" rid="bibr80-0272989X11407341">80</xref>,<xref ref-type="bibr" rid="bibr81-0272989X11407341">81</xref></sup> Indeed, the cluster-specific criteria developed are intended to complement generic checklists and guidelines for statistical methods in CEA. Second, although a careful search strategy was undertaken to try and capture all published studies that used CRTs, if the article did not include appropriate index terms that enabled us to identify a CEA that used data from CRTs, a relevant study could have been omitted. However, to minimize this problem, the search strategy did include many alternative search terms for CEA and CRT. Third, when the reviewers applied the checklists, they were not blinded to the paper’s title and authorship, and so the possibility for investigator bias cannot be ruled out. Fourth, it is plausible that studies may have used appropriate methods but did not report them. Distinguishing between inappropriate methods and inadequate reporting of appropriate methods is a general challenge facing researchers who conduct critical appraisals.<sup><xref ref-type="bibr" rid="bibr32-0272989X11407341">32</xref>,<xref ref-type="bibr" rid="bibr33-0272989X11407341">33</xref></sup> Our findings suggest that there is room for improvement in both the methods used and the reporting of those methods in CEAs that use CRTs.</p>
<p>In conclusion, economic evaluations that use CRTs frequently ignore clustering in the data or correlation between costs and outcomes. Statistical methods that address these issues are available, andtheir use should be encouraged to help these studies provide a sound basis for policy making. Methodological guidelines for the evaluation of public health interventions<sup><xref ref-type="bibr" rid="bibr5-0272989X11407341">5</xref></sup> could incorporate the additional criteria developed. Our proposed checklist can help raise awareness of poor research practice and provide a starting point for improving the quality of economic evaluations that use CRTs. The checklist can be updated to recognize future methodological developments.</p>
</sec>
</body>
<back>
<ack>
<p>The authors thank Edmond Ng, Simon Thompson, James Carpenter, Andrew Hutchings, Zia Sadique, Catherine Pitt, and Noemi Kreif for their help and comments. They thank Jane Morrell (PI) and Simon Dixon for permission to use, and for providing access to, the PoNDER data. They also thank participants at the Health Economists’ Study Group meeting, at the London School of Economics, January 2010, where this paper was presented. In particular, they thank Helen Dakin for her thoughtful discussion.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial support: Doctoral scholarship from Fundação para a Ciência e a Tecnologia (MG) and postdoctoral fellowship from National Institute of Health Research (RG).</p>
</fn>
<fn fn-type="supplementary-material">
<p>Supplementary material for this article is available on the <italic>Medical Decision Making</italic> Web site at <ext-link ext-link-type="uri" xlink:href="http://mdm.sagepub.com/supplemental">http://mdm.sagepub.com/supplemental</ext-link>.</p>
</fn>
<fn fn-type="other" id="fn1-0272989X11407341">
<label>*</label>
<p>The ICC reports the proportion of the total variation that is at the cluster rather than the individual level.</p>
</fn>
<fn fn-type="other" id="fn2-0272989X11407341">
<label>†</label>
<p>For (clustered) continuous outcomes, marginal and conditional analyses provide the same estimates.<sup><xref ref-type="bibr" rid="bibr67-0272989X11407341">67</xref></sup></p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0272989X11407341">
<label>1.</label>
<citation citation-type="book">
<collab>National Institute for Health and Clinical Excellence (NICE)</collab>. <source>Methods for Technology Appraisal</source>. <publisher-loc>London, UK</publisher-loc>: <publisher-name>NICE</publisher-name>; <year>2008</year>.</citation>
</ref>
<ref id="bibr2-0272989X11407341">
<label>2.</label>
<citation citation-type="book">
<collab>Canadian Agency for Drugs and Technologies in Health (CADTH)</collab>. <source>Guidelines for the Economic Evaluation of Health Technologies: Canada</source>. <edition>3rd ed.</edition> <publisher-loc>Ottawa, Canada</publisher-loc>: <publisher-name>CADTH</publisher-name>; <year>2006</year>.</citation>
</ref>
<ref id="bibr3-0272989X11407341">
<label>3.</label>
<citation citation-type="book">
<collab>Pharmaceutical Benefits Advisory Committee (PBAC)</collab>. <source>Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee</source>. <publisher-loc>Canberra, Australia</publisher-loc>: <publisher-name>Australian Government—Department of Health and Ageing</publisher-name>; <year>2008</year>.</citation>
</ref>
<ref id="bibr4-0272989X11407341">
<label>4.</label>
<citation citation-type="book">
<collab>Institute for Quality and Efficiency in Health Care (IQWIG)</collab>. <source>Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System</source>. <publisher-loc>Cologne, Germany</publisher-loc>: <publisher-name>IQWIG</publisher-name>; <year>2009</year>.</citation>
</ref>
<ref id="bibr5-0272989X11407341">
<label>5.</label>
<citation citation-type="book">
<collab>National Institute for Health and Clinical Excellence (NICE)</collab>. <source>Methods for Development of NICE Public Health Guidance</source>. <publisher-loc>London, UK</publisher-loc>: <publisher-name>NICE</publisher-name>; <year>2009</year>.</citation>
</ref>
<ref id="bibr6-0272989X11407341">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grieve</surname><given-names>R</given-names></name>
<name><surname>Sekhon</surname><given-names>JS</given-names></name>
<name><surname>Hu</surname><given-names>TW</given-names></name>
<name><surname>Bloom</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Evaluating health care programs by combining cost with quality of life measures: a case study comparing capitation and fee for service</article-title>. <source>Health Serv Res</source>. <year>2008</year>;<volume>43</volume>(<issue>4</issue>):<fpage>1204</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr7-0272989X11407341">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hutchings</surname><given-names>A</given-names></name>
<name><surname>Durand</surname><given-names>MA</given-names></name>
<name><surname>Grieve</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Evaluation of modernisation of adult critical care services in England: time series and cost effectiveness analysis</article-title>. <source>BMJ</source>. <year>2009</year>;<volume>339</volume>:<fpage>b4353</fpage>.</citation>
</ref>
<ref id="bibr8-0272989X11407341">
<label>8.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Drummond</surname><given-names>M</given-names></name>
<name><surname>Sculpher</surname><given-names>M</given-names></name>
<name><surname>Torrance</surname><given-names>GW</given-names></name>
<name><surname>O’Brien</surname><given-names>BJ</given-names></name>
<name><surname>Stoddart</surname><given-names>GL</given-names></name>
</person-group>. <source>Methods for the Economic Evaluation of Health Care Programmes</source>. <edition>3rd ed.</edition> <publisher-loc>Oxford, UK</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>; <year>2005</year>.</citation>
</ref>
<ref id="bibr9-0272989X11407341">
<label>9.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Glick</surname><given-names>HA</given-names></name>
<name><surname>Doshi</surname><given-names>JA</given-names></name>
<name><surname>Sonnad</surname><given-names>SS</given-names></name>
<name><surname>Polsky</surname><given-names>D</given-names></name>
</person-group>. <source>Economic Evaluation in Clinical Trials</source>. <publisher-loc>Oxford, UK</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>; <year>2007</year>.</citation>
</ref>
<ref id="bibr10-0272989X11407341">
<label>10.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Gold</surname><given-names>MR</given-names></name>
</person-group>. <source>Cost-Effectiveness in Health and Medicine</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>; <year>1996</year>.</citation>
</ref>
<ref id="bibr11-0272989X11407341">
<label>11.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Willan</surname><given-names>A</given-names></name>
<name><surname>Briggs</surname><given-names>A</given-names></name>
</person-group>. <source>Statistical Analysis of Cost-Effectiveness Data</source>. <publisher-loc>Chichester, UK</publisher-loc>: <publisher-name>John Wiley</publisher-name>; <year>2006</year>.</citation>
</ref>
<ref id="bibr12-0272989X11407341">
<label>12.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Donner</surname><given-names>A</given-names></name>
<name><surname>Klar</surname><given-names>N</given-names></name>
</person-group>. <source>Design and Analysis of Cluster Randomization Trials in Health Research</source>. <publisher-loc>London, UK</publisher-loc>: <publisher-name>Hodder Arnold Publishers</publisher-name>; <year>2000</year>.</citation>
</ref>
<ref id="bibr13-0272989X11407341">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Donner</surname><given-names>A</given-names></name>
<name><surname>Klar</surname><given-names>N</given-names></name>
</person-group>. <article-title>Pitfalls of and controversies in cluster randomization trials</article-title>. <source>Am J Public Health</source>. <year>2004</year>;<volume>94</volume>(<issue>3</issue>):<fpage>416</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr14-0272989X11407341">
<label>14.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Hayes</surname><given-names>R</given-names></name>
<name><surname>Moulton</surname><given-names>L</given-names></name>
</person-group>. <article-title>Regression analysis based on individual-level data</article-title>. In: <person-group person-group-type="editor">
<name><surname>Keiding</surname><given-names>N</given-names></name>
<name><surname>Morgan</surname><given-names>B</given-names></name>
<name><surname>Wikle</surname><given-names>C</given-names></name>
<name><surname>van der Heijden</surname><given-names>P</given-names></name>
</person-group>, eds. <source>Cluster Randomised Trials</source>. <publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>CRC Press, Taylor &amp; Francis</publisher-name>; <year>2009</year>.</citation>
</ref>
<ref id="bibr15-0272989X11407341">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klar</surname><given-names>N</given-names></name>
<name><surname>Donner</surname><given-names>A</given-names></name>
</person-group>. <article-title>Current and future challenges in the design and analysis of cluster randomization trials</article-title>. <source>Stat Med</source>. <year>2001</year>;<volume>20</volume>(<issue>24</issue>):<fpage>3729</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr16-0272989X11407341">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Murray</surname><given-names>DM</given-names></name>
<name><surname>Varnell</surname><given-names>SP</given-names></name>
<name><surname>Blitstein</surname><given-names>JL</given-names></name>
</person-group>. <article-title>Design and analysis of group-randomized trials: a review of recent methodological developments</article-title>. <source>Am J Public Health</source>. <year>2004</year>;<volume>94</volume>(<issue>3</issue>):<fpage>423</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr17-0272989X11407341">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ukoumunne</surname><given-names>OC</given-names></name>
<name><surname>Gulliford</surname><given-names>MC</given-names></name>
<name><surname>Chinn</surname><given-names>S</given-names></name>
<name><surname>Sterne</surname><given-names>JA</given-names></name>
<name><surname>Burney</surname><given-names>PG</given-names></name>
</person-group>. <article-title>Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review</article-title>. <source>Health Technol Assess</source>. <year>1999</year>;<volume>3</volume>(<issue>5</issue>):<fpage>iii</fpage>–<lpage>92</lpage>.</citation>
</ref>
<ref id="bibr18-0272989X11407341">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>MJ</given-names></name>
<name><surname>Donner</surname><given-names>A</given-names></name>
<name><surname>Klar</surname><given-names>N</given-names></name>
</person-group>. <article-title>Developments in cluster randomized trials and Statistics in Medicine</article-title>. <source>Stat Med</source>. <year>2007</year>;<volume>26</volume>(<issue>1</issue>):<fpage>2</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr19-0272989X11407341">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Omar</surname><given-names>RZ</given-names></name>
<name><surname>Thompson</surname><given-names>SG</given-names></name>
</person-group>. <article-title>Analysis of a cluster randomized trial with binary outcome data using a multi-level model</article-title>. <source>Stat Med</source>. <year>2000</year>;<volume>19</volume>(<issue>19</issue>):<fpage>2675</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr20-0272989X11407341">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spiegelhalter</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>Bayesian methods for cluster randomized trials with continuous responses</article-title>. <source>Stat Med</source>. <year>2001</year>;<volume>20</volume>(<issue>3</issue>):<fpage>435</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr21-0272989X11407341">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Turner</surname><given-names>RM</given-names></name>
<name><surname>Omar</surname><given-names>RZ</given-names></name>
<name><surname>Thompson</surname><given-names>SG</given-names></name>
</person-group>. <article-title>Bayesian methods of analysis for cluster randomized trials with binary outcome data</article-title>. <source>Stat Med</source>. <year>2001</year>;<volume>20</volume>(<issue>3</issue>):<fpage>453</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr22-0272989X11407341">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Briggs</surname><given-names>AH</given-names></name>
<name><surname>O’Brien</surname><given-names>BJ</given-names></name>
</person-group>. <article-title>The death of cost-minimization analysis?</article-title> <source>Health Econ</source>. <year>2001</year>;<volume>10</volume>(<issue>2</issue>):<fpage>179</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr23-0272989X11407341">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoch</surname><given-names>JS</given-names></name>
<name><surname>Briggs</surname><given-names>AH</given-names></name>
<name><surname>Willan</surname><given-names>AR</given-names></name>
</person-group>. <article-title>Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis</article-title>. <source>Health Econ</source>. <year>2002</year>;<volume>11</volume>(<issue>5</issue>):<fpage>415</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr24-0272989X11407341">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nixon</surname><given-names>RM</given-names></name>
<name><surname>Thompson</surname><given-names>SG</given-names></name>
</person-group>. <article-title>Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations</article-title>. <source>Health Econ</source>. <year>2005</year>;<volume>14</volume>(<issue>12</issue>):<fpage>1217</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr25-0272989X11407341">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Willan</surname><given-names>AR</given-names></name>
<name><surname>Briggs</surname><given-names>AH</given-names></name>
<name><surname>Hoch</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data</article-title>. <source>Health Econ</source>. <year>2004</year>;<volume>13</volume>(<issue>5</issue>):<fpage>461</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr26-0272989X11407341">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mihaylova</surname><given-names>B</given-names></name>
<name><surname>Briggs</surname><given-names>A</given-names></name>
<name><surname>O’Hagan</surname><given-names>A</given-names></name>
<name><surname>Thompson</surname><given-names>SG</given-names></name>
</person-group>. <article-title>Review of statistical methods for analysing healthcare resources and costs</article-title>. <source>Health Econ</source>. <year>2010</year>;<volume>27</volume>(<issue>15</issue>):<fpage>101</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr27-0272989X11407341">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nixon</surname><given-names>RM</given-names></name>
<name><surname>Thompson</surname><given-names>SG</given-names></name>
</person-group>. <article-title>Parametric modelling of cost data in medical studies</article-title>. <source>Stat Med</source>. <year>2004</year>;<volume>23</volume>(<issue>8</issue>):<fpage>1311</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr28-0272989X11407341">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>SG</given-names></name>
<name><surname>Nixon</surname><given-names>RM</given-names></name>
</person-group>. <article-title>How sensitive are cost-effectiveness analyses to choice of parametric distributions?</article-title> <source>Med Decis Making</source>. <year>2005</year>;<volume>25</volume>(<issue>4</issue>):<fpage>416</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr29-0272989X11407341">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bachmann</surname><given-names>MO</given-names></name>
<name><surname>Fairall</surname><given-names>L</given-names></name>
<name><surname>Clark</surname><given-names>A</given-names></name>
<name><surname>Mugford</surname><given-names>M</given-names></name>
</person-group>. <article-title>Methods for analyzing cost effectiveness data from cluster randomized trials</article-title>. <source>Cost Eff Resour Alloc</source>. <year>2007</year>;<volume>5</volume>:<fpage>12</fpage>.</citation>
</ref>
<ref id="bibr30-0272989X11407341">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Flynn</surname><given-names>TN</given-names></name>
<name><surname>Peters</surname><given-names>TJ</given-names></name>
</person-group>. <article-title>Cluster randomized trials: another problem for cost-effectiveness ratios</article-title>. <source>Int J Technol Assess Health Care</source>. <year>2005</year>;<volume>21</volume>(<issue>3</issue>):<fpage>403</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr31-0272989X11407341">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grieve</surname><given-names>R</given-names></name>
<name><surname>Nixon</surname><given-names>R</given-names></name>
<name><surname>Thompson</surname><given-names>SG</given-names></name>
</person-group>. <article-title>Bayesian hierarchical models for cost-effectiveness analyses that use data fromcluster randomized trials</article-title>. <source>Med Decis Making</source>. <year>2010</year>;<volume>30</volume>(<issue>2</issue>):<fpage>163</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr32-0272989X11407341">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Philips</surname><given-names>Z</given-names></name>
<name><surname>Bojke</surname><given-names>L</given-names></name>
<name><surname>Sculpher</surname><given-names>M</given-names></name>
<name><surname>Claxton</surname><given-names>K</given-names></name>
<name><surname>Golder</surname><given-names>S</given-names></name>
</person-group>. <article-title>Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment</article-title>. <source>Pharmacoeconomics</source>. <year>2006</year>;<volume>24</volume>(<issue>4</issue>):<fpage>355</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr33-0272989X11407341">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Evers</surname><given-names>S</given-names></name>
<name><surname>Goossens</surname><given-names>M</given-names></name>
<name><surname>de Vet</surname><given-names>H</given-names></name>
<name><surname>van Tulder</surname><given-names>M</given-names></name>
<name><surname>Ament</surname><given-names>A</given-names></name>
</person-group>. <article-title>Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria</article-title>. <source>Int J Technol Assess Health Care</source>. <year>2005</year>;<volume>21</volume>(<issue>2</issue>):<fpage>240</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr34-0272989X11407341">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Graves</surname><given-names>N</given-names></name>
<name><surname>Walker</surname><given-names>D</given-names></name>
<name><surname>Raine</surname><given-names>R</given-names></name>
<name><surname>Hutchings</surname><given-names>A</given-names></name>
<name><surname>Roberts</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods</article-title>. <source>Health Econ</source>. <year>2002</year>;<volume>11</volume>(<issue>8</issue>):<fpage>735</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr35-0272989X11407341">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hjelmgren</surname><given-names>J</given-names></name>
<name><surname>Berggren</surname><given-names>F</given-names></name>
<name><surname>Andersson</surname><given-names>F</given-names></name>
</person-group>. <article-title>Health economic guidelines similarities, differences and some implications</article-title>. <source>Value Health</source>. <year>2001</year>;<volume>4</volume>(<issue>3</issue>):<fpage>225</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr36-0272989X11407341">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ofman</surname><given-names>JJ</given-names></name>
<name><surname>Sullivan</surname><given-names>SD</given-names></name>
<name><surname>Neumann</surname><given-names>PJ</given-names></name><etal/>
</person-group>. <article-title>Examining the value and quality of health economic analyses: implications of utilizing the QHES</article-title>. <source>J Manag Care Pharm</source>. <year>2003</year>;<volume>9</volume>(<issue>1</issue>):<fpage>53</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr37-0272989X11407341">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ramsey</surname><given-names>S</given-names></name>
<name><surname>Willke</surname><given-names>R</given-names></name>
<name><surname>Briggs</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Good research practicesfor cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report</article-title>. <source>Value Health</source>. <year>2005</year>;<volume>8</volume>(<issue>5</issue>):<fpage>521</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr38-0272989X11407341">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Willan</surname><given-names>A</given-names></name>
</person-group>. <article-title>Statistical analysis of cost-effectiveness data from randomised clinical trials</article-title>. <source>Expert Rev Pharmacoecon Outcomes Res</source>. <year>2006</year>;<volume>6</volume>:<fpage>337</fpage>–<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr39-0272989X11407341">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moerbeek</surname><given-names>M</given-names></name>
<name><surname>van Breukelen</surname><given-names>GJ</given-names></name>
<name><surname>Berger</surname><given-names>MP</given-names></name>
</person-group>. <article-title>Design issues for experiments in multilevel populations</article-title>. <source>J Educ Behav Stat</source>. <year>2000</year>;<volume>25</volume>(<issue>3</issue>):<fpage>271</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr40-0272989X11407341">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Donner</surname><given-names>A</given-names></name>
</person-group>. <article-title>Some aspects of the design and analysis of cluster randomization trials</article-title>. <source>Appl Stat</source>. <year>1998</year>;<volume>47</volume>:<fpage>95</fpage>–<lpage>113</lpage>.</citation>
</ref>
<ref id="bibr41-0272989X11407341">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hayes</surname><given-names>RJ</given-names></name>
<name><surname>Bennett</surname><given-names>S</given-names></name>
</person-group>. <article-title>Simple sample size calculation for cluster-randomized trials</article-title>. <source>Int J Epidemiol</source>. <year>1999</year>;<volume>28</volume>(<issue>2</issue>):<fpage>319</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr42-0272989X11407341">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Feng</surname><given-names>ZD</given-names></name>
<name><surname>McLerran</surname><given-names>D</given-names></name>
<name><surname>Grizzle</surname><given-names>J</given-names></name>
</person-group>. <article-title>A comparison of statistical methods for clustered data analysis with Gaussian error</article-title>. <source>Stat Med</source>. <year>1996</year>;<volume>15</volume>(<issue>16</issue>):<fpage>1793</fpage>–<lpage>806</lpage>.</citation>
</ref>
<ref id="bibr43-0272989X11407341">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ukoumunne</surname><given-names>OC</given-names></name>
<name><surname>Thompson</surname><given-names>SG</given-names></name>
</person-group>. <article-title>Analysis of cluster randomized trials with repeated cross-sectional binary measurements</article-title>. <source>Stat Med</source>. <year>2001</year>;<volume>20</volume>(<issue>3</issue>):<fpage>417</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr44-0272989X11407341">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Panageas</surname><given-names>KS</given-names></name>
<name><surname>Schrag</surname><given-names>D</given-names></name>
<name><surname>Russell Localio</surname><given-names>A</given-names></name>
<name><surname>Venkatraman</surname><given-names>ES</given-names></name>
<name><surname>Begg</surname><given-names>CB</given-names></name>
</person-group>. <article-title>Properties of analysis methods that account for clustering in volume-outcome studies when the primary predictor is cluster size</article-title>. <source>Stat Med</source>. <year>2007</year>;<volume>26</volume>(<issue>9</issue>):<fpage>2017</fpage>–<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr45-0272989X11407341">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Al</surname><given-names>MJ</given-names></name>
<name><surname>van Hout</surname><given-names>BA</given-names></name>
<name><surname>Michel</surname><given-names>BC</given-names></name>
<name><surname>Rutten</surname><given-names>FF</given-names></name>
</person-group>. <article-title>Sample size calculation in economic evaluations</article-title>. <source>Health Econ</source>. <year>1998</year>;<volume>7</volume>(<issue>4</issue>):<fpage>327</fpage>–<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr46-0272989X11407341">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Briggs</surname><given-names>A</given-names></name>
</person-group>. <article-title>Economic evaluation and clinical trials: size matters</article-title>. <source>BMJ</source>. <year>2000</year>;<volume>321</volume>(<issue>7273</issue>):<fpage>1362</fpage>–<lpage>3</lpage>.</citation>
</ref>
<ref id="bibr47-0272989X11407341">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drummond</surname><given-names>M</given-names></name>
<name><surname>O’Brien</surname><given-names>B</given-names></name>
</person-group>. <article-title>Clinical importance, statistical significance and the assessment of economic and quality-of-life outcomes</article-title>. <source>Health Econ</source>. <year>1993</year>;<volume>2</volume>(<issue>3</issue>):<fpage>205</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr48-0272989X11407341">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Sullivan</surname><given-names>AK</given-names></name>
<name><surname>Thompson</surname><given-names>D</given-names></name>
<name><surname>Drummond</surname><given-names>MF</given-names></name>
</person-group>. <article-title>Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations?</article-title> <source>Value Health</source>. <year>2005</year>;<volume>8</volume>(<issue>1</issue>):<fpage>67</fpage>–<lpage>79</lpage>.</citation>
</ref>
<ref id="bibr49-0272989X11407341">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bland</surname><given-names>JM</given-names></name>
</person-group>. <article-title>The tyranny of power: is there a better way to calculate sample size?</article-title> <source>BMJ</source>. <year>2009</year>;<volume>339</volume>:<fpage>b3985</fpage>.</citation>
</ref>
<ref id="bibr50-0272989X11407341">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>MK</given-names></name>
<name><surname>Fayers</surname><given-names>PM</given-names></name>
<name><surname>Grimshaw</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Determinants of the intracluster correlation coefficient in cluster randomized trials: the case of implementation research</article-title>. <source>Clin Trials</source>. <year>2005</year>;<volume>2</volume>(<issue>2</issue>):<fpage>99</fpage>–<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr51-0272989X11407341">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grieve</surname><given-names>R</given-names></name>
<name><surname>Nixon</surname><given-names>R</given-names></name>
<name><surname>Thompson</surname><given-names>SG</given-names></name>
<name><surname>Normand</surname><given-names>C</given-names></name>
</person-group>. <article-title>Using multilevel models for assessing the variability of multinational resource use and cost data</article-title>. <source>Health Econ</source>. <year>2005</year>;<volume>14</volume>(<issue>2</issue>):<fpage>185</fpage>–<lpage>96</lpage>.</citation>
</ref>
<ref id="bibr52-0272989X11407341">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>SG</given-names></name>
<name><surname>Nixon</surname><given-names>RM</given-names></name>
<name><surname>Grieve</surname><given-names>R</given-names></name>
</person-group>. <article-title>Addressing the issues that arise in analysing multicentre cost data, with application to a multinational study</article-title>. <source>J Health Econ</source>. <year>2006</year>;<volume>25</volume>(<issue>6</issue>):<fpage>1015</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr53-0272989X11407341">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Hagan</surname><given-names>A</given-names></name>
<name><surname>Stevens</surname><given-names>JW</given-names></name>
<name><surname>Montmartin</surname><given-names>J</given-names></name>
</person-group>. <article-title>Bayesian cost-effectiveness analysis from clinical trial data</article-title>. <source>Stat Med</source>. <year>2001</year>;<volume>20</volume>(<issue>5</issue>):<fpage>733</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr54-0272989X11407341">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Briggs</surname><given-names>A</given-names></name>
<name><surname>Nixon</surname><given-names>R</given-names></name>
<name><surname>Dixon</surname><given-names>S</given-names></name>
<name><surname>Thompson</surname><given-names>S</given-names></name>
</person-group>. <article-title>Parametric modelling of cost data: some simulation evidence</article-title>. <source>Health Econ</source>. <year>2005</year>;<volume>14</volume>(<issue>4</issue>):<fpage>421</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr55-0272989X11407341">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manning</surname><given-names>WG</given-names></name>
<name><surname>Basu</surname><given-names>A</given-names></name>
<name><surname>Mullahy</surname><given-names>J</given-names></name>
</person-group>. <article-title>Generalized modeling approaches to risk adjustment of skewed outcomes data</article-title>. <source>J Health Econ</source>. <year>2005</year>;<volume>24</volume>(<issue>3</issue>):<fpage>465</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr56-0272989X11407341">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manning</surname><given-names>WG</given-names></name>
<name><surname>Mullahy</surname><given-names>J</given-names></name>
</person-group>. <article-title>Estimating log models: to transform or not to transform?</article-title> <source>J Health Econ</source>. <year>2001</year>;<volume>20</volume>(<issue>4</issue>):<fpage>461</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr57-0272989X11407341">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grieve</surname><given-names>R</given-names></name>
<name><surname>Nixon</surname><given-names>R</given-names></name>
<name><surname>Thompson</surname><given-names>SG</given-names></name>
<name><surname>Cairns</surname><given-names>J</given-names></name>
</person-group>. <article-title>Multilevel models for estimating incremental net benefits in multinational studies</article-title>. <source>Health Econ</source>. <year>2007</year>;<volume>16</volume>(<issue>8</issue>):<fpage>815</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr58-0272989X11407341">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morrell</surname><given-names>CJ</given-names></name>
<name><surname>Warner</surname><given-names>R</given-names></name>
<name><surname>Slade</surname><given-names>P</given-names></name><etal/>
</person-group>. <article-title>Psychological interventions for postnatal depression: cluster randomised trial and economic evaluation. The PoNDER trial</article-title>. <source>Health Technol Assess</source>. <year>2009</year>;<volume>13</volume>(<issue>30</issue>):<comment>iii–iv, xi–xiii</comment>, <fpage>1</fpage>–<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr59-0272989X11407341">
<label>59.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Goldstein</surname><given-names>H</given-names></name>
</person-group>. <source>Multilevel Statistical Models</source>. <edition>3rd ed.</edition> <publisher-loc>Oxford, UK</publisher-loc>: <publisher-name>Oxford University Press</publisher-name>; <year>2003</year>.</citation>
</ref>
<ref id="bibr60-0272989X11407341">
<label>60.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Leyland</surname><given-names>A</given-names></name>
<name><surname>Goldstein</surname><given-names>H</given-names></name>
</person-group>. <source>Multilevel Modelling of Health Statistics</source>. <publisher-loc>Chichester, UK</publisher-loc>: <publisher-name>John Wiley</publisher-name>; <year>2001</year>.</citation>
</ref>
<ref id="bibr61-0272989X11407341">
<label>61.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Hardin</surname><given-names>JW</given-names></name>
<name><surname>Hilbe</surname><given-names>JM</given-names></name>
</person-group>. <source>Generalized Estimating Equations</source>. <publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>Chapman &amp; Hall/CRC</publisher-name>; <year>2003</year>.</citation>
</ref>
<ref id="bibr62-0272989X11407341">
<label>62.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Davison</surname><given-names>AC</given-names></name>
<name><surname>Hinkley</surname><given-names>DV</given-names></name>
</person-group>. In: <person-group person-group-type="editor">
<name><surname>Gill</surname><given-names>R</given-names></name>
<name><surname>Ripley</surname><given-names>BD</given-names></name>
<name><surname>Ross</surname><given-names>S</given-names></name>
<name><surname>Stein</surname><given-names>M</given-names></name>
<name><surname>Williams</surname><given-names>D</given-names></name>
</person-group>, eds. <source>Bootstrap Methods and Their Application.</source> <publisher-loc>Cambridge, UK</publisher-loc>: <publisher-name>Cambridge University Press;</publisher-name> <year>1997</year>.</citation>
</ref>
<ref id="bibr63-0272989X11407341">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lipsitz</surname><given-names>S</given-names></name>
<name><surname>Fitzmaurice</surname><given-names>G</given-names></name>
<name><surname>Ibrahim</surname><given-names>J</given-names></name>
<name><surname>Sinha</surname><given-names>D</given-names></name>
<name><surname>Parzen</surname><given-names>M</given-names></name>
<name><surname>Lipshultz</surname><given-names>S</given-names></name>
</person-group>. <article-title>Joint generalized estimating equations for multivariate longitudinal binary outcomes with missing data: an application to acquired immune deficiency syndrome data</article-title>. <source>J Roy Stat Soc A</source>. <year>2009</year>;<volume>172</volume>(<issue>pt 1</issue>):<fpage>3</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr64-0272989X11407341">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liang</surname><given-names>KY</given-names></name>
<name><surname>Zeger</surname><given-names>S</given-names></name>
</person-group>. <article-title>Longitudinal data analysis using generalized linear models</article-title>. <source>Biometrika</source>. <year>1986</year>;<volume>73</volume>(<issue>1</issue>):<fpage>13</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr65-0272989X11407341">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Austin</surname><given-names>PC</given-names></name>
</person-group>. <article-title>A comparison of the statistical power of different methods for the analysis of cluster randomization trials with binary outcomes</article-title>. <source>Stat Med</source>. <year>2007</year>;<volume>26</volume>(<issue>19</issue>):<fpage>3550</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr66-0272989X11407341">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Turner</surname><given-names>RM</given-names></name>
<name><surname>White</surname><given-names>IR</given-names></name>
<name><surname>Croudace</surname><given-names>T</given-names></name>
</person-group>. <article-title>Analysis of cluster randomized cross-over trial data: a comparison of methods</article-title>. <source>Stat Med</source>. <year>2007</year>;<volume>26</volume>(<issue>2</issue>):<fpage>274</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr67-0272989X11407341">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>AY</given-names></name>
<name><surname>Nelder</surname><given-names>J</given-names></name>
</person-group>. <article-title>Conditional and marginal models: another view</article-title>. <source>Stat Sci</source>. <year>2004</year>;<volume>19</volume>(<issue>2</issue>):<fpage>219</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr68-0272989X11407341">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Briggs</surname><given-names>AH</given-names></name>
<name><surname>Mooney</surname><given-names>CZ</given-names></name>
<name><surname>Wonderling</surname><given-names>DE</given-names></name>
</person-group>. <article-title>Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation</article-title>. <source>Stat Med</source>. <year>1999</year>;<volume>18</volume>(<issue>23</issue>):<fpage>3245</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr69-0272989X11407341">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nixon</surname><given-names>RM</given-names></name>
<name><surname>Wonderling</surname><given-names>D</given-names></name>
<name><surname>Grieve</surname><given-names>RD</given-names></name>
</person-group>. <article-title>Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared</article-title>. <source>Health Econ</source>. <year>2010</year>;<volume>19</volume>(<issue>3</issue>):<fpage>316</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr70-0272989X11407341">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Hagan</surname><given-names>A</given-names></name>
<name><surname>Stevens</surname><given-names>JW</given-names></name>
</person-group>. <article-title>Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?</article-title> <source>Health Econ</source>. <year>2003</year>;<volume>12</volume>(<issue>1</issue>):<fpage>33</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr71-0272989X11407341">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Flynn</surname><given-names>TN</given-names></name>
<name><surname>Peters</surname><given-names>TJ</given-names></name>
</person-group>. <article-title>Use of the bootstrap in analysing cost data from cluster randomised trials: some simulation results</article-title>. <source>BMC Health Serv Res</source>. <year>2004</year>;<volume>4</volume>:<fpage>33</fpage>–<lpage>43</lpage>.</citation>
</ref>
<ref id="bibr72-0272989X11407341">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moher</surname><given-names>D</given-names></name>
<name><surname>Liberati</surname><given-names>A</given-names></name>
<name><surname>Tetzlaff</surname><given-names>J</given-names></name>
<name><surname>Altman</surname><given-names>DG</given-names></name>
</person-group>. <article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>. <source>BMJ</source>. <year>2009</year>;<volume>339</volume>:<fpage>b2535</fpage>.</citation>
</ref>
<ref id="bibr73-0272989X11407341">
<label>73.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Briggs</surname><given-names>AH</given-names></name>
</person-group>. <article-title>A Bayesian approach to stochastic cost-effectiveness analysis</article-title>. <source>Health Econ</source>. <year>1999</year>;<volume>8</volume>(<issue>3</issue>):<fpage>257</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr74-0272989X11407341">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Philips</surname><given-names>Z</given-names></name>
<name><surname>Ginnelly</surname><given-names>L</given-names></name>
<name><surname>Sculpher</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Review of guidelines for good practice in decision-analytic modelling in health technology assessment</article-title>. <source>Health Technol Assess</source>. <year>2004</year>;<volume>8</volume>(<issue>36</issue>):<comment>iii–iv, ix–xi</comment>, <fpage>1</fpage>–<lpage>158</lpage>.</citation>
</ref>
<ref id="bibr75-0272989X11407341">
<label>75.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sculpher</surname><given-names>MJ</given-names></name>
<name><surname>Pang</surname><given-names>FS</given-names></name>
<name><surname>Manca</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Generalisability in economic evaluation studies in healthcare: a review and case studies</article-title>. <source>Health Technol Assess</source>. <year>2004</year>;<volume>8</volume>(<issue>49</issue>):iii–iv, <fpage>1</fpage>–<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr76-0272989X11407341">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rivero-Arias</surname><given-names>O</given-names></name>
<name><surname>Gray</surname><given-names>A</given-names></name>
</person-group>. <article-title>The multinational nature of cost-effectiveness analyses alongside multinational clinical trials</article-title>. <source>Value Health</source>. <year>2010</year>;<volume>13</volume>(<issue>1</issue>):<fpage>34</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr77-0272989X11407341">
<label>77.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Turner</surname><given-names>RM</given-names></name>
<name><surname>Omar</surname><given-names>RZ</given-names></name>
<name><surname>Thompson</surname><given-names>SG</given-names></name>
</person-group>. <article-title>Modelling multivariate outcomes in hierarchical data, with application to cluster randomised trials</article-title>. <source>Biom J</source>. <year>2006</year>;<volume>48</volume>(<issue>3</issue>):<fpage>333</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr78-0272989X11407341">
<label>78.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Briggs</surname><given-names>AH</given-names></name>
<name><surname>Gray</surname><given-names>AM</given-names></name>
</person-group>. <article-title>Handling uncertainty when performing economic evaluation of healthcare interventions</article-title>. <source>Health Technol Assess</source>. <year>1999</year>;<volume>3</volume>(<issue>2</issue>):<fpage>1</fpage>–<lpage>134</lpage>.</citation>
</ref>
<ref id="bibr79-0272989X11407341">
<label>79.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eldridge</surname><given-names>SM</given-names></name>
<name><surname>Ashby</surname><given-names>D</given-names></name>
<name><surname>Feder</surname><given-names>GS</given-names></name>
<name><surname>Rudnicka</surname><given-names>AR</given-names></name>
<name><surname>Ukoumunne</surname><given-names>OC</given-names></name>
</person-group>. <article-title>Lessons for cluster randomized trials in the twenty-first century: a systematic review of trials in primary care</article-title>. <source>Clin Trials</source>. <year>2004</year>;<volume>1</volume>(<issue>1</issue>):<fpage>80</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr80-0272989X11407341">
<label>80.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manca</surname><given-names>A</given-names></name>
<name><surname>Palmer</surname><given-names>S</given-names></name>
</person-group>. <article-title>Handling missing data in patient-level cost-effectiveness analysis alongside randomised clinical trials</article-title>. <source>Appl Health Econ Health Policy</source>. <year>2005</year>;<volume>4</volume>(<issue>2</issue>):<fpage>65</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr81-0272989X11407341">
<label>81.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Willan</surname><given-names>AR</given-names></name>
<name><surname>Lin</surname><given-names>DY</given-names></name>
<name><surname>Manca</surname><given-names>A</given-names></name>
</person-group>. <article-title>Regression methods for cost-effectiveness analysis with censored data</article-title>. <source>Stat Med</source>. <year>2005</year>;<volume>24</volume>(<issue>1</issue>): <fpage>131</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr82-0272989X11407341">
<label>82.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Donner</surname><given-names>A</given-names></name>
<name><surname>Klar</surname><given-names>N</given-names></name>
</person-group>. <article-title>Methods for comparing event rates in intervention studies when the unit of allocation is a cluster</article-title>. <source>Am J Epidemiol</source>. <year>1994</year>;<volume>140</volume>(<issue>3</issue>):<fpage>279</fpage>–<lpage>89</lpage>; <comment>discussion 300–1</comment>.</citation>
</ref>
<ref id="bibr83-0272989X11407341">
<label>83.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Feng</surname><given-names>Z</given-names></name>
<name><surname>Diehr</surname><given-names>P</given-names></name>
<name><surname>Peterson</surname><given-names>A</given-names></name>
<name><surname>McLerran</surname><given-names>D</given-names></name>
</person-group>. <article-title>Selected statistical issues in group randomized trials</article-title>. <source>Annu Rev Public Health</source>. <year>2001</year>;<volume>22</volume>:<fpage>167</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr84-0272989X11407341">
<label>84.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Efron</surname><given-names>B</given-names></name>
<name><surname>Tibshirani</surname><given-names>R</given-names></name>
</person-group>. <source>An Introduction to Bootstrap</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Chapman &amp; Hall</publisher-name>; <year>1993</year>.</citation>
</ref>
<ref id="bibr85-0272989X11407341">
<label>85.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manca</surname><given-names>A</given-names></name>
<name><surname>Lambert</surname><given-names>PC</given-names></name>
<name><surname>Sculpher</surname><given-names>M</given-names></name>
<name><surname>Rice</surname><given-names>N</given-names></name>
</person-group>. <article-title>Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modeling</article-title>. <source>Med Decis Making</source>. <year>2007</year>;<volume>27</volume>(<issue>4</issue>):<fpage>471</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr86-0272989X11407341">
<label>86.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Briggs</surname><given-names>A</given-names></name>
<name><surname>Gray</surname><given-names>A</given-names></name>
</person-group>. <article-title>The distribution of health care costs and their statistical analysis for economic evaluation</article-title>. <source>J Health Serv Res Policy</source>. <year>1998</year>;<volume>3</volume>(<issue>4</issue>):<fpage>233</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr87-0272989X11407341">
<label>87.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Manning</surname><given-names>WG</given-names></name>
</person-group>. <article-title>The logged dependent variable, heteroscedasticity, and the retransformation problem</article-title>. <source>J Health Econ</source>. <year>1998</year>;<volume>17</volume>(<issue>3</issue>):<fpage>283</fpage>–<lpage>95</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>